RE: Numis sell note3 Nov 2023 06:54
A very poorly written note IMHO.
"However, more targeted drugs already exist. We also note a broad range of later-stage drugs targeting soft tissue sarcoma and believe the opportunity for AVA600 is more limited than the company and the market believe. "
From..... Frontiers in Oncology _National Library of Medicine.
Over the past two decades there has been significant advancement in the use of targeted therapies for the treatment of advanced and metastatic STS. These developments in targeted therapies have highlighted a key paradigm and future direction of treatment. Continuing in this vein, and building on the success of the prior years, it is easy to see that the future of treatment in sarcoma is bright. Next generation sequencing of STS in later lines will continue to improve, and with it, our ability to identify actionable targets. The promise of treatments that minimize toxicity, while maximizing on target efficacy is hard to ignore, and with the rapid pace of development, may shortly be in reach.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034045/